{"organizations": [], "uuid": "1f7645c62318b097f2b855fd719f51cd9c8b5347", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indias-bal-pharma-dec-qtr-profit-r/brief-indias-bal-pharma-dec-qtr-profit-rises-idUSFWN1Q411K", "country": "US", "domain_rank": 408, "title": "BRIEF-India's Bal Pharma Dec-Qtr Profit Rises", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.308, "site_type": "news", "published": "2018-02-14T20:32:00.000+02:00", "replies_count": 0, "uuid": "1f7645c62318b097f2b855fd719f51cd9c8b5347"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indias-bal-pharma-dec-qtr-profit-r/brief-indias-bal-pharma-dec-qtr-profit-rises-idUSFWN1Q411K", "ord_in_thread": 0, "title": "BRIEF-India's Bal Pharma Dec-Qtr Profit Rises", "locations": [], "entities": {"persons": [{"name": "sanjay kumar", "sentiment": "none"}], "locations": [{"name": "india", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-india", "sentiment": "negative"}, {"name": "bal pharma ltd", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - India’s Bal Pharma Ltd:\n* DEC QUARTER NET PROFIT 17.4 MILLION RUPEES VERSUS PROFIT OF 15.9 MILLION RUPEES YEAR AGO\n* DEC QUARTER REVENUE FROM OPERATIONS 519.4 MILLION RUPEES VERSUS 584.4 MILLION RUPEES YEAR AGO\n* SAYS ACCEPTED RESIGNATION OF SANJAY KUMAR AGARWAL FROM POST OF CFO\n* APPROVED SIGNING OF JOINT VENTURE AGREEMENT WITH AKAAL PHARMA FOR DEVELOPMENT AND MARKETING OF VETERINARY MEDICINES​ Source text - bit.ly/2Eul5Qb Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2Eul5Qb"], "published": "2018-02-14T20:32:00.000+02:00", "crawled": "2018-02-15T20:43:58.000+02:00", "highlightTitle": ""}